Get the Daily Brief
Latest Biotech News
New inflammatory immunology startup funding – Bionyra launches with TL1A program
Bionyra Pharma emerged from stealth with a $165 million launch, betting on the TL1A target with three early-stage immune drugs. Co-founded by Sofinnova Partners and led by former Sanofi immunology...
Precision transplant care – Pirche and Natera pair risk scores with dd-cfDNA monitoring
Pirche and Natera announced a collaboration to connect pre-transplant risk stratification with post-transplant monitoring for transplant patients. Under the agreement, Pirche will pair its...
Phase 3 breakthrough in ulcerative colitis – Merck’s anti-TL1A antibody posts positive induction results
Merck reported a positive result for its anti-TL1A antibody tulisokibart in the ATLAS-UC induction-only Phase 3 study in moderately to severely active ulcerative colitis. The company said the...
FDA reversal on gene therapy pathway – Regenxbio to resubmit Hunter syndrome treatment
Regenxbio said it will resubmit its Hunter syndrome gene therapy after what it described as another shift in FDA position following leadership departures. The biotech’s plan follows an earlier FDA...
Late-stage depression data – Definium reports Phase 3 LSD therapy benefit
Definium Therapeutics said its LSD-based treatment DT120 significantly improved major depression symptoms in its first Phase 3 trial. Six weeks after a single dose, the company reported a...
CRISPR gene editing momentum – Intellia stock surges on additional HAELO endpoints
Intellia’s stock rallied after the company reported additional positive secondary endpoint data for lonvoguran ziclumeran (lonvo-z) in the pivotal Phase 3 HAELO trial for hereditary angioedema....
Funding for neurodegeneration – Nura Bio raises $73.8M for SARM1 inhibitor programs
Nura Bio raised $73.8 million in a Series B to advance two early clinical programs targeting SARM1, a pathway implicated in axon degeneration. The funding is intended to support progression...
AI-enabled neuroscience drug discovery partnership – Insilico and SK Biopharmaceuticals expand neuroimmune work
Insilico Medicine and SK Biopharmaceuticals entered a neuroimmune-focused R&D collaboration at BIO 2026 that could be worth more than $2.5 billion. Insilico will use its Pharma.AI platform to...
Clinical trial design for biosimilars – Canada removes Phase III requirement, FDA drafts major shift
Canada has eliminated a Phase III trial requirement for biosimilar approvals, according to the report. The policy change comes as the U.S. FDA also proposed to substantially eliminate the need in...
Capital and pipeline momentum in neurodegeneration
Nura Bio secured a $73.8 million Series B round to advance SARM1 inhibitor programs for neurodegeneration, the company said. The funding is intended to support two clinical-stage efforts through...
Late-stage CRISPR momentum in hereditary angioedema
Intellia Therapeutics extended support for its CRISPR portfolio in hereditary angioedema after a second positive Phase III data release in two months. The company’s lonvoguran ziclumeran (lonvo-z)...
Eczema candidate funding to reach the clinic
Triveni Bio closed a $65 million Series C to advance TRIV-573, its bispecific candidate for atopic dermatitis. The company said proceeds will fund clinical development tied to its eczema program,...
Deal-making surge in pharma-biotech M&A
Pharmaceutical companies have stepped up acquisition activity, with STAT+ reporting 32 biotech acquisitions valued at $1 billion or more in the past six months. The figure reflects a heightened...
AI drug discovery partnership with SK Biopharm
Insilico Medicine and SK Biopharmaceuticals announced an AI-enabled drug discovery collaboration focused on neuroimmune disorders, with deal economics potentially exceeding $2.5 billion. The...
US trade probe targets Germany’s drug pricing rules
The U.S. Trade Representative launched an investigation into Germany’s drug pricing policies, arguing the U.S. shoulders a disproportionate share of biopharma R&D burden. USTR ambassador Jamieson...
Corporate leadership shift at Sanofi R&D
Sanofi said its R&D chief, Houman Ashrafian, will exit as newly appointed CEO Belén Garijo moves to reshape the company’s R&D leadership. Paulo Fontoura, M.D., Ph.D., will replace Ashrafian as...
Biologics safety signal quantification for T-cell bispecifics
A systematic review and meta-analysis estimated second primary malignant neoplasms (SPMs) following treatment with T-cell–engaging bispecific antibodies used in B-cell non-Hodgkin lymphoma and...
Engineering microalgae-based microbots for targeted bladder cancer delivery
Researchers engineered microalgae-powered microbots designed to deliver chemotherapy directly into bladder tumors with guidance from magnetic fields and monitoring via real-time imaging. The...
Cell biology mechanism: autophagy and centrosome control
A Nature Communications study by Coelho, Fatalska, Geymonat and colleagues mapped molecular crosstalk that monitors and regulates centrosome numbers, linking centriole biology to autophagy. The...
Clinical readouts and regulatory path for CRISPR therapy in hereditary angioedema
Intellia Therapeutics’ lonvoguran ziclumeran (lonvo-z) added another layer of late-stage support after the company reported new positive results tied to secondary endpoints in its Phase III HAELO...